{"id":2242,"date":"2026-01-14T09:57:01","date_gmt":"2026-01-14T01:57:01","guid":{"rendered":"https:\/\/www.hanchorbio.com\/?post_type=news&p=2242"},"modified":"2026-02-26T11:23:22","modified_gmt":"2026-02-26T03:23:22","slug":"hanchorbio-participating-in-the-j-p-morgan-healthcare-conference-2026","status":"publish","type":"news","link":"https:\/\/www.hanchorbio.com\/en\/news\/hanchorbio-participating-in-the-j-p-morgan-healthcare-conference-2026\/","title":{"rendered":"HanchorBio Participating in the J.P. Morgan Healthcare Conference 2026"},"content":{"rendered":"
\"\"<\/div>\n
\n

HanchorBio Participating in the J.P. Morgan Healthcare Conference 2026<\/strong><\/h3>\n

As the holiday season approaches, HanchorBio is kicking off 2026 with active engagement at one of the industry\u2019s most important global healthcare events.\u00a0HanchorBio is participating in the J.P. Morgan Healthcare Conference 2026<\/strong>, held\u00a0January 12\u201315, 2026, in San Francisco<\/strong>.<\/p>\n

During the conference,\u00a0Scott Liu, PhD, Founder, Chairman, and CEO,\u00a0<\/strong>Alvin Luk, PhD, MBA<\/strong>,\u00a0President & Chief Medical Officer (Group) and Chief Executive Officer (U.S.)<\/strong>, together with\u00a0Yuehua Cong, PhD<\/strong>,\u00a0Chief Business Officer<\/strong>, are on site meeting with global partners, investors, and industry leaders to discuss collaboration opportunities and HanchorBio\u2019s strategic growth.<\/p>\n

\"HanchorBio-Participating-In-The-J.P.-Morgan-Healthcare-Conference-2026\"<\/p>\n<\/article>\n

HanchorBio is advancing\u00a0next-generation innate-immunity biologics<\/strong>\u00a0aimed at transforming cancer immunotherapy, including:<\/p>\n

    \n
  • \n

    HCB101<\/strong>, a next-generation\u00a0CD47\u2013SIRP\u03b1 fusion protein<\/strong>\u00a0designed as an innate-immune backbone for combination therapies with PD-1 inhibitors, anti-VEGF agents, HER2-targeted therapies, EGFR inhibitors, antibody\u2013drug conjugates (ADCs), and radiotherapy<\/p>\n<\/li>\n

  • \n

    HCB301<\/strong>, a\u00a0tri-specific SIRP\u03b1\u2013PD-L1\u2013TGF\u03b2 fusion protein<\/strong>\u00a0designed to reprogram macrophage and T-cell biology<\/p>\n<\/li>\n

  • \n

    FBDB\u2122<\/strong>, HanchorBio\u2019s multi-specific protein engineering platform, enabling programmable immune re-balancing across multiple tumor types<\/p>\n<\/li>\n<\/ul>\n

    Through innovative science and platform-driven development, HanchorBio remains committed to\u00a0transforming immunotherapy and advancing health for all<\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":"

    HanchorBio Participating in the J.P. Morgan Healthcare Conference 2026 As the holiday season approaches, HanchorBio is kicking off 2026 with active engagement at one of the industry\u2019s most important global healthcare events.\u00a0HanchorBio is participating in the J.P. Morgan Healthcare Conference 2026, held\u00a0January 12\u201315, 2026, in San Francisco. During the conference,\u00a0Scott Liu, PhD, Founder, Chairman, and […]<\/p>\n","protected":false},"featured_media":2244,"template":"","news-category":[],"class_list":["post-2242","news","type-news","status-publish","has-post-thumbnail","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news\/2242","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/types\/news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/media\/2244"}],"wp:attachment":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/media?parent=2242"}],"wp:term":[{"taxonomy":"news-category","embeddable":true,"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news-category?post=2242"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}